Propedix Welcomes Dr. Mercedes E. Gonzalez to Clinical Advisory Board
Propedix Strengthens Clinical Advisory Board with New Appointment
In an exciting development for the company, Propedix Inc. has officially announced the appointment of Dr. Mercedes E. Gonzalez, a board-certified pediatric dermatologist, to its Clinical Advisory Board. Effective immediately, this strategic move is set to bolster Propedix's capabilities in pediatric dermatology and innovation in treatment solutions.
Dr. Gonzalez is not just a well-respected physician; she is also the founder and Medical Director of Derm360 and the Medical Director of Pediatric Skin Research, LLC. Her impressive academic credentials include positions as Clinical Assistant Professor at several institutions such as Florida International University and University of Miami. Additionally, her leadership roles on the Board of Directors of the American Board of Dermatology and the Society for Pediatric Dermatology Practice Management highlight her extensive experience in the field.
A Commitment to Advancing Pediatric Dermatology
Dr. Gonzalez is known for her fervent commitment to clinical research, particularly regarding enhancing access to innovative therapies for children suffering from skin diseases. Her forward-thinking approach aligns perfectly with Propedix’s mission to improve outcomes for patients through cutting-edge solutions.
“We are thrilled to welcome Dr. Gonzalez to the Propedix Clinical Advisory Board,” stated Dr. Carl Schanbacher, Founder and Chief Medical Officer of Propedix. “Her extensive expertise in pediatric dermatology, coupled with her leadership in research and education, will be invaluable as we continue to innovate in topical treatments for fungal conditions.”
Dr. Gonzalez expressed her enthusiasm for joining the advisory board, stating, “I am honored to be part of Propedix. Their innovative DryStik technology and the clinical efficacy of Dryello for athletes foot resonate deeply with my dedication to enhancing patient outcomes.”
The Innovative DryStik Technology
Propedix is renowned for its innovative approach to topical dermatology and anti-infective treatments. Their proprietary DryStik™ delivery system stands out in the market, aimed at effectively delivering antifungal treatments. With an emphasis on providing clinically tested solutions, Propedix is actively working on expanding its treatment portfolio.
The company’s upcoming launches include products targeting dermatological issues such as Foot Anti-Perspirant, Jock Itch, Ringworm, and Candida, all expected to roll out throughout 2026. Their flagship product, Dryello™, which is a formulation containing tolnaftate, has shown promise in effectively treating athlete's foot.
Advancements in Dermatological Treatments
According to clinical trials, Dryello™ demonstrates strong efficacy in treating fungal infections, effectively addressing common symptoms like itching, sweating, and skin scaling. The strategic addition of Dr. Gonzalez to the advisory board is expected to accelerate the development of these treatments, enhancing the company's growth trajectory and solidifying its position in the dermatological field.
As Propedix continues to make strides in innovative treatment solutions, the appointment of Dr. Mercedes E. Gonzalez marks a pivotal step in their commitment to enhancing the quality of life for individuals suffering from skin conditions. With her on board, the future looks bright for Propedix and the patients they serve.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.